• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment.

作者信息

Hultcrantz Malin, Rustad Even Holth, Yellapantula Venkata, Arcila Maria, Ho Caleb, Syed Mustafa H, Papaemmanuil Elli, Zhang Yanming, Maura Francesco, Landgren Ola

机构信息

Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Hematopathology Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Blood Cancer J. 2020 Jul 22;10(7):76. doi: 10.1038/s41408-020-00343-w.

DOI:10.1038/s41408-020-00343-w
PMID:32699232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7376205/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e2/7376205/5720bf2133b0/41408_2020_343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e2/7376205/5720bf2133b0/41408_2020_343_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e2/7376205/5720bf2133b0/41408_2020_343_Fig1_HTML.jpg

相似文献

1
Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment.使用靶向测序NGS检测法进行基线VDJ克隆型检测：以便后续进行微小残留病评估。
Blood Cancer J. 2020 Jul 22;10(7):76. doi: 10.1038/s41408-020-00343-w.
2
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.多发性骨髓瘤微小残留病灶检测中 V(D)J 测序的捕获率。
Clin Cancer Res. 2022 May 13;28(10):2160-2166. doi: 10.1158/1078-0432.CCR-20-2995.
3
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.克隆免疫球蛋白 CDR3 序列在多发性骨髓瘤微小残留病灶监测中的稳定性和独特性。
Am J Hematol. 2019 Dec;94(12):1364-1373. doi: 10.1002/ajh.25641. Epub 2019 Oct 21.
4
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.下一代测序技术在多发性骨髓瘤中升级的标准化微小残留病灶检测。
J Mol Diagn. 2020 May;22(5):679-684. doi: 10.1016/j.jmoldx.2020.02.005. Epub 2020 Mar 6.
5
Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.全面描绘微小残留病灶中循环和骨髓衍生多发性骨髓瘤细胞的特征。
Semin Hematol. 2018 Jan;55(1):33-37. doi: 10.1053/j.seminhematol.2018.02.010. Epub 2018 Mar 1.
6
Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.多发性骨髓瘤可测量残留病灶（MRD）评估的最佳实践。
Clin Adv Hematol Oncol. 2020 Jan;18 Suppl 1(1):1-20.
7
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.多骨髓瘤中克隆型评估和微小残留病灶监测的下一代测序策略的实验室间分析验证。
Arch Pathol Lab Med. 2022 Jul 1;146(7):862-871. doi: 10.5858/arpa.2021-0088-OA.
8
[Prognostic value of minimal residual disease detection in multiple myeloma].[微小残留病检测在多发性骨髓瘤中的预后价值]
Nihon Rinsho. 2015 Jan;73(1):69-73.
9
Minimal residual disease analysis in myeloma - when, why and where.骨髓瘤中的微小残留病分析——时机、原因及地点
Leuk Lymphoma. 2018 Aug;59(8):1772-1784. doi: 10.1080/10428194.2017.1386304. Epub 2017 Oct 11.
10
Molecular detection of minimal residual disease in multiple myeloma.多发性骨髓瘤微小残留病的分子检测。
Br J Haematol. 2018 Apr;181(1):11-26. doi: 10.1111/bjh.15075. Epub 2017 Dec 19.

引用本文的文献

1
Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion?单细胞测序揭示多发性骨髓瘤进展机制：明晰还是困惑？
Ann Hematol. 2025 Feb;104(2):895-912. doi: 10.1007/s00277-025-06241-0. Epub 2025 Feb 7.
2
Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma.循环肿瘤DNA的组织匹配IgH基因重排对预测弥漫性大B细胞淋巴瘤进展具有重要价值。
Oncologist. 2024 May 3;29(5):e672-e680. doi: 10.1093/oncolo/oyae008.
3
Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes-A feasibility study.
基于液体活检分析免疫球蛋白基因重排监测多发性骨髓瘤残留病灶：一项可行性研究。
PLoS One. 2023 May 26;18(5):e0285696. doi: 10.1371/journal.pone.0285696. eCollection 2023.
4
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.单细胞 RNA 测序检测多发性骨髓瘤中的克隆型 V(D)J 重排。
Int J Mol Sci. 2022 Dec 10;23(24):15691. doi: 10.3390/ijms232415691.
5
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.多发性骨髓瘤的风险分层治疗展望。
Blood Cancer Discov. 2022 Jul 6;3(4):273-284. doi: 10.1158/2643-3230.BCD-21-0205.
6
Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.多发性骨髓瘤微小残留病灶检测中 V(D)J 测序的捕获率。
Clin Cancer Res. 2022 May 13;28(10):2160-2166. doi: 10.1158/1078-0432.CCR-20-2995.
7
Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.单细胞 RNA 测序揭示复发多发性骨髓瘤的克隆多样性和预后基因。
Clin Transl Med. 2022 Mar;12(3):e757. doi: 10.1002/ctm2.757.